9 research outputs found
Antibiotic use in elderly patients in ambulatory care: A comparison between Hungary and Sweden
Background: The elderly use antibiotics frequently due to their increasing infection susceptibility. Given the high and increasing proportion of elderly in the population, their antibiotic use is substantial. Objective: This study aimed to compare antibiotic use in the elderly in the ambulatory care sector between Hungary and Sweden
Variation in the prices of oncology medicines across Europe and the implications for the future
Introduction/ Objectives: There are increasing concerns among health authorities regarding the sustainability of healthcare systems with growing expenditure on medicines including new high-priced oncology medicines. Medicine prices among European countries may be adversely affected by their population size and economic power to negotiate. There are also concerns that prices of patented medicines do not change once the prices of medicines used for negotiations substantially change. This needs to be investigated as part of the implications of low-cost generic oncology medicines. Methodology: Analysing principally reimbursed prices of patented oral oncology medicines (imatinib, erlotinib and fludarabine) between 2013 and 2017 across Europe and exploring correlations between GDP, population size, and prices. Comparing the findings with previous research regarding prices of oral generic oncology medicines. Results: The prices of imatinib, erlotinib and fludarabine did vary among European countries but showed limited price erosion over time in the absence of generics. There appeared to be no correlation between population size and prices. However, higher prices were seen among countries with higher GDP per capita which is a concern for lower income countries referencing these. Discussion and Conclusion: It is likely that the limited price erosion for patented oncology medicines will change across Europe with increased scrutiny over their prices and value as more medicines used for pricing decisions lose their patents combined with growing pressures on the oncology drug budget. In addition, discussions will continue regarding fair pricing for new oncology medicines and other approaches given ever rising prices with research showing substantial price reductions for oral oncology medicines (up to -97.8% for imatinib) once generics become available. We are also seeing appreciable price reductions for biosimilars further increasing the likelihood of these developments
A temporary regulation to manage an impending shortage due to extraordinary prescribing patterns of chloroquines observed during early phase of COVID-19 epidemic
Background: Chloroquine and hydroxychloroquine (C/HC) received considerable international media attention due to anticipated treatment effect in COVID-19. This led to increased prescriptions threatening to generate product shortages for patients prescribed within approved indications.We evaluated effects of a temporary regulation mandating pharmacies to only dispense C/HC prescribed by physicians with defined specialties. Methods: Data from Region Stockholm, which include 2.4 out of 10 million Sweden’s population, were used. Weekly time trends of prescriptions and requisitions of C/HC by prescriber’s workplace during January to April 2020 were followed. Results: Numbers of unique individuals with filled prescriptions of chloroquine increased tenfold and of hydroxychloroquine more than threefold from January to March. In the first week of April, filled prescriptions of C/HC dropped. In the later weeks of April, the number of filled prescriptions was back at similar levels as before the SARS-CoV-2 outbreak.During January and February, specialists in rheumatology accounted for 686 out of all 979 prescriptions dispensed (70.1%) of C/HC. In March, a large proportion of prescriptions dispensed were from specialists not usually prescribing C/HC, and rheumatology accounted for 628 out of all 1,639 prescriptions (38.3%). In April, specialists in rheumatology accounted for 386 out of all 641 prescriptions dispensed (60.0%). Conclusion: After an observed increase in prescriptions of C/HC, a temporary regulation was introduced on 2nd April 2020 to reduce prescriptions from specialists not usually prescribing C/HC to avoid shortages for patients within approved indications. Subsequently, dispensed prescriptions decreased from April and remained at pre-COVID-19 levels thereafter
Antibiotic use in elderly patients in ambulatory care: A comparison between Hungary and Sweden
Background: The elderly use antibiotics frequently due to their increasing infection susceptibility. Given the high and increasing proportion of elderly in the population, their antibiotic use is substantial. Objective: This study aimed to compare antibiotic use in the elderly in the ambulatory care sector between Hungary and Sweden. Methods: This retrospective, descriptive, cross-national, comparative study
included antibacterial use data from the Hungarian National Health
Insurance Fund and the Swedish eHealth Agency. Antibiotic use (anatomical
therapeutical chemical: J01) was expressed as the number of prescriptions/
1000 inhabitants/year or month and was further stratified by age and sex.
Results: Antibiotic exposure was higher in the Hungarian elderly population
(649.8 prescriptions/1000 inhabitants/year) compared to its Swedish
counterparts (545.0 prescriptions/1000 inhabitants/year). Hungary had a
similar scale of antibacterial exposure across all elderly age subgroups, with
different trends in males and females, while Sweden had a stepwise increase in
antibiotic exposure by age in both sexes. The seasonal fluctuation was high in
Hungary and reached a peak of 80.7 prescriptions/1000 inhabitants/month in
January 2017, while even antibiotic use was detected throughout the year in
Sweden. The pattern of antibiotic use in the elderly considerably differed
between the two countries. Penicillin and beta-lactamase combinations,
such as co-amoxiclav, were more frequently used in Hungary than in
Sweden (19.08% vs 1.83% of corresponding total ambulatory antibiotic use).
Likewise, quinolones were more commonly used in Hungary than in Sweden
(34.53% vs. 9.98). The elderly in Sweden were mostly prescribed narrow spectra
penicillins (26.71% vs. 0.29% in Hungary). Conclusion: This cross-national comparison revealed important differences in
all aspects of antibiotic use in the elderly between the two countries. The
identical scale and pattern of antibiotic use cannot be anticipated due to the
poorer health status of the Hungarian elderly population. However, the
substantial differences indicate some room for improvement in the antibiotic
prescription for the Hungarian elderly
Patients’ knowledge and attitudes to the Wise List - a drug formulary from the Stockholm Drug and Therapeutic committee
Abstract Background Involving patients in decisions about their pharmacotherapy is crucial for a satisfactory treatment outcome. Information and opinions about medicines are available from a variety of sources. The Wise List is the drug formulary of recommended essential medicines for the Stockholm healthcare region and is issued by the Drug and Therapeutics Committee (DTC). To inform the public about treatment for common diseases and the concept of recommended medicines, a patient edition of the Wise List was developed. The aim of this study was to explore patients’ knowledge, needs and attitudes to the Wise List, DTC and information about medicines in general. Methods To examine patient knowledge about recommended medicines a survey (n = 312) was carried out at four large primary healthcare centres in Stockholm, Sweden. To further elucidate the patients’ needs of the information on recommended medicines and medicines in general, three focus group discussions (FGDs) were performed. Results Of the respondents 57% did not recognise the Wise List, 26% recognised but did not use it and 17% used it. A total of 63% reported that they search for information about medicines. The most common information source was “asking their doctor” (36%) followed by searching the internet (31%). The FGDs revealed that the patients were not interested in medicines in general, only in the medicines they use themselves. They did not understand the aim of the Wise List or how they could benefit from information about recommended medicines. The patients expressed a wish to access all information they need about their own care as well as public healthcare information at one location. Conclusion The intended aim of the DTC with providing information to the public was not achieved as the patients have difficulties to understand the information and how they should use it. The patients were not interested in medicines in general, they wanted information tailored to their specific needs. The findings highlight the importance of creating tools for patients in collaboration with them and evaluate the concept continuously
Patients’ knowledge and attitudes to the Wise List - a drug formulary from the Stockholm Drug and Therapeutic committee
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacture
Variation in the prices of oncology medicines across Europe and the implications for the future
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Introduction: There are appreciable concerns among European health
authorities with growing expenditure on cancer medicines and issues of
sustainability. The enhanced use of low-cost generics could help.
Aims: Consequently, there is a need to comprehensively document current
and future arrangements regarding the pricing of generic cancer
medicines across Europe, and whether these are indication specific, as
well as how this translates into actual prices to provide future
direction.
Methodology: Mixed-method approach with qualitative research among
senior health authority personnel and their advisers. Quantitative
research via health authority databases to ascertain current prices for
oral cancer medicines that had lost their patent and the influence of
population size and economics on prices.
Results: Twenty-five European countries participated. The research found
the following issues: (a) variable approaches to the pricing of generic
cancer medicines, which will continue; (b) no concerns with substitution
for oral generic cancer medicines; (c) substantial price reductions
versus originators for generic capecitabine (up to -93.1%), generic
imatinib (up to -97.8%) and generic temozolomide (up to -80.7%).
Prices for oncology medicines are not generally indication specific, and
are not affected by population size although influenced by pricing
approaches. There have also been price increases for some non-patented
cancer medicines following manufacturer changes although now
stabilizing.
Conclusion: The considerable price reductions seen for some generics
means health authorities should further encourage the use of generic
oncology medicines when they become available to fund increased volumes
and new valued cancer medicines. Countries are also starting to address
price increases for generics following changes in the manufacturer